Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
RESEARCH TOOLSreports
BUX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.38
Previous CloseN/A
Volume0.00
Average Volume (3M)14.35K
Market Cap
C$33.63M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Jul 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,886,230
10 Day Avg. Volume23,302
30 Day Avg. Volume14,354
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.18 and its highest was C$0.38 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$33.63M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Jul 29, 2025 which is yesterday.
How were BioMark Diagnostics’s earnings last quarter?
Currently, no data Available
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 90,886,230 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Technical Analysis
Diagnos
―
Medivolve Inc
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
Sona Nanotech Inc
―
Ownership Overview
55.44% Insiders
―
Mutual Funds
― Other Institutional Investors
44.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---